Phibro Animal Health (PAHC) Gross Profit Margin starting from the first quarter 2026 to first quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Phibro Animal Health Corporation  (NASDAQ: PAHC)


Phibro Animal Health's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PAHC Gross Profit Margin (Sep 30 2026)
Q1 		(Jun 30 2026)
Q4 		(Mar 31 2026)
Q3 		(Dec 31 2025)
Q2 		(Sep 30 2025)
Q1
Y / Y Revenue Change 6.32 %
Seq. Revenue Change -2.51 %
Revenue In Millions $386.77
Gross Profit Margin 33.23 %
Gross Profit Margin Total Ranking # 2397
Gross Profit In Millions $128.54
Y / Y Gross Profit Change 7.31 %
Seq. Gross Profit Change -4.36 %


Commenting First Quarter 2026 Gross Profit Margin
Phibro Animal Health Corporation experienced contraction in Gross Profit by -4.36 % to $387 millions and Revenue by -2.51 %, while Gross Profit Margin fell to 33.23 %, above company*s average Gross Profit Margin.


Observing first quarter 2026 results within Major Pharmaceutical Preparations industry 130 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 2397, from total ranking in the previous quarter at 2494.
Learn about Gross Margin
PAHC's Gross Profit Margin first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 131
Healthcare Sector # 378
Overall # 2377

Gross Profit Margin Statistics
High Average Low
35.5 % 31.74 % 28.95 %
(Dec 31 2025)   (Jun 30 2025)


PAHC Gross Income Trends • More of PAHC's Profitabilty Ratios • PAHC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
PAHC's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
PAHC's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for PAHC's Competitors
Gross Profit Margin Profit Margin for Phibro Animal Health's Suppliers
Gross Profit Margin Profit Margin for PAHC's Customers

You may also want to know
PAHC's Annual Growth Rates PAHC's Profitability Ratios PAHC's Asset Turnover Ratio PAHC's Dividend Growth
PAHC's Roe PAHC's Valuation Ratios PAHC's Financial Strength Ratios PAHC's Gross Profit Growth
PAHC's Roa PAHC's Inventory Turnover Ratio PAHC's Growth Rates PAHC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Arcutis Biotherapeutics Inc   91.34 %$ 131.459  Millions$ 143.919  Millions
Roivant Sciences Ltd   90.47 %$ 31.774  Millions$ 35.121  Millions
Kiniksa Pharmaceuticals International Plc  90.29 %$ 258.211  Millions$ 285.970  Millions
Aurinia Pharmaceuticals Inc   90.08 %$ 75.393  Millions$ 83.699  Millions
Acadia Pharmaceuticals Inc   89.75 %$ 307.201  Millions$ 342.291  Millions
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Ocular Therapeutix Inc   88.70 %$ 11.419  Millions$ 12.874  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions
United Therapeutics Corporation  88.10 %$ 733.400  Millions$ 832.500  Millions
Supernus Pharmaceuticals inc   88.09 %$ 199.753  Millions$ 226.771  Millions
Aclaris Therapeutics Inc   87.24 %$ 1.292  Millions$ 1.481  Millions
Ligand Pharmaceuticals Incorporated  87.04 %$ 68.541  Millions$ 78.746  Millions
Liquidia Corporation  86.88 %$ 195.746  Millions$ 225.300  Millions
Rhythm Pharmaceuticals Inc   86.79 %$ 79.962  Millions$ 92.128  Millions
Rigel Pharmaceuticals Inc  86.67 %$ 70.107  Millions$ 80.890  Millions
Newamsterdam Pharma Company N v   86.11 %$ 16.503  Millions$ 19.164  Millions
Indivior Pharmaceuticals Inc   85.67 %$ 305.000  Millions$ 356.000  Millions
Insmed Inc  85.09 %$ 446.213  Millions$ 524.428  Millions
Vertex Pharmaceuticals Inc  84.71 %$ 2,914.700  Millions$ 3,440.800  Millions
Eli Lilly And Company  83.88 %$ 20,464.000  Millions$ 24,397.000  Millions
Tg Therapeutics Inc   83.81 %$ 217.857  Millions$ 259.936  Millions
Akebia Therapeutics Inc   82.76 %$ 30.541  Millions$ 36.903  Millions
Renovorx Inc   82.36 %$ 0.878  Millions$ 1.066  Millions
Alkermes Plc   80.38 %$ 385.912  Millions$ 480.132  Millions
Biomarin Pharmaceutical Inc  79.95 %$ 819.230  Millions$ 1,024.646  Millions
Innoviva Inc   79.52 %$ 84.382  Millions$ 106.120  Millions
Pacira Biosciences inc   78.92 %$ 139.420  Millions$ 176.653  Millions
Phathom Pharmaceuticals Inc   78.32 %$ 66.355  Millions$ 84.722  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.